Piron Lauranne, Deshayes Emmanuel, Escal Laure, Souche Regis, Herrero Astrid, Pierredon-Foulongne Marie-Ange, Assenat Eric, le Lam Ngo, Quenet François, Guiu Boris
Saint-Éloi University Hospital, Department of Radiology, 80, avenue Augustin-Fliche, 34090 Montpellier, France.
Institut du Cancer de Montpellier, Department of Nuclear Medicine, 208, avenue des Apothicaires, 34298 Montpellier, France; Inserm U1194, 208, avenue des Apothicaires, 34298 Montpellier, France.
Bull Cancer. 2017 May;104(5):407-416. doi: 10.1016/j.bulcan.2017.03.009. Epub 2017 May 3.
Portal vein embolization consists of occluding a part of the portal venous system in order to achieve the hypertrophy of the non-embolized liver segments. This technique is used during the preoperative period of major liver resection when the future remnant liver (FRL) volume is insufficient, exposing to postoperative liver failure, main cause of death after major hepatectomy. Portal vein embolization indication depends on the FRL, commonly assessed by its volume. Nowadays, FRL function evaluation seems more relevant and can be measured by 99mTc labelled mebrofenin scintigraphy. Portal vein embolization procedure is mostly performed with percutaneous trans-hepatic access by using ultrasonography guidance and consists of embolic agent injection, such as cyanoacrylate, in the targeted portal vein branches with fluoroscopic guidance. It is a safe and well-tolerated technique, with extremely low morbi-mortality. Portal vein embolization leads to sufficient FRL hypertrophy in about 80% of patients, allowing them to undergo surgery from which they were initially rejected. The two main reasons of non-resection are tumor progression (≈15% of cases) and FRL insufficient hypertrophy (≈5% of cases). When portal vein embolization is not enough to obtain adequate FRL regeneration, hepatic vein embolization may potentiate its effect (liver venous deprivation technique).
门静脉栓塞术是指闭塞门静脉系统的一部分,以实现未栓塞肝段的肥大。当未来残余肝(FRL)体积不足,有术后肝衰竭风险(肝大部切除术后主要死因)时,该技术用于肝大部切除术前。门静脉栓塞术的适应证取决于FRL,通常通过其体积来评估。如今,FRL功能评估似乎更为重要,可通过99mTc标记的美罗芬宁闪烁扫描法进行测量。门静脉栓塞术大多在超声引导下经皮经肝穿刺进行,在透视引导下向目标门静脉分支注射栓塞剂,如氰基丙烯酸酯。这是一种安全且耐受性良好的技术,病死率极低。门静脉栓塞术可使约80%的患者FRL充分肥大,使他们能够接受原本无法进行的手术。无法进行手术的两个主要原因是肿瘤进展(约15%的病例)和FRL肥大不足(约5%的病例)。当门静脉栓塞不足以实现充分的FRL再生时,肝静脉栓塞可增强其效果(肝静脉剥夺技术)。